echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancer: Short-term (2-3 years) adjuvant endocrine therapy is an optional treatment option for breast cancer patients with ER-positive low expression (IHC 1%-10%)

    Cancer: Short-term (2-3 years) adjuvant endocrine therapy is an optional treatment option for breast cancer patients with ER-positive low expression (IHC 1%-10%)

    • Last Update: 2022-04-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital , mainly evaluating the use of short-course (2-3 years) adjuvant in patients with ER-positive low-expression (IHC 1%-10%) breast cancer.


    Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital .


    From 2012 to 2017, 22,768 patients were pathologically confirmed early breast cancer, of which 1013 (4.


    From 2012 to 2017, 22,768 patients were pathologically confirmed early breast cancer, of which 1013 (4.


    At a median follow-up of 65 months (interquartile range 44-72 months), the estimated 5-year DFS rate for the entire study cohort was 85.


    At a median follow-up of 65 months (interquartile range 44-72 months), the estimated 5-year DFS rate for the entire study cohort was 85.


    The results showed that in univariate analysis (HR, 0.


    The results showed that in univariate analysis (HR, 0.


    In propensity-matched post-analysis, univariate analysis showed no significant improvement in DFS in patients who received 5 years of endocrine therapy compared with those who received 2 to 3 years of endocrine therapy (HR, 0.


    In propensity-matched post-analysis, univariate analysis showed no significant improvement in DFS in patients who received 5 years of endocrine therapy compared with those who received 2 to 3 years of endocrine therapy (HR, 0.


    There were no statistically significant differences in DFS in subgroup analyses of patients with endocrine therapy for 2-3 years and 5 years before and after propensity-matched analysis


    We also examined changes in ER status in recurrent lesions in ER-positive, low-expressing breast cancers .


    We also examined changes in ER status in recurrent lesions in ER-positive, low-expressing breast cancers .


    In conclusion, the study shows that for patients with ER-positive low expression (IHC 1%-10%) breast cancer, short-course (2-3 years) adjuvant endocrine therapy is the treatment option of choice


    Original source:

    Cai YW, Shao ZM, Yu KD.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.